
Serum Institute of India gets DCGI permission to restart phase 2, 3 trials of coronavirus COVID-19 vaccine
The Serum Institute of India (SII) is all set to restart its phase two and three clinical trials for the COVID-19 vaccine after getting the nod from the Drugs Controller General of India (DCGI).
According to ANI, the SII had sought permission from the DGCI to restart the re-enrollment procedure for COVID-19 vaccine which is being developed by AstraZeneca and Oxford University following the Data Safety Monitoring Board (DSMB) recommendations.
“You (SII) may recommence the clinical trial dated August 2, 2020, as recommended by the DSMB, India as per already approved protocol and the provisions laid down under New Drugs and Clinical Trials Rules, 2019 subject to the conditions mentioned which are to be scrupulously followed such as extra care during screening, additional information in the informed consent and close monitoring for similar events during the study follow-up,” the DCGI said in its letter to the Serum Institute.
On September 8, AstraZeneca had announced that it “voluntarily paused” the phase 3 clinical human trials of its vaccine candidate ‘Covishield’ after one of the volunteers got ill.
“As part of the ongoing randomized, controlled global trials of the Oxford coronavirus vaccine, our standard review process was triggered and we voluntarily paused vaccination to allow a review of safety data by an independent committee,” the pharma major had said in a statement.
The vaccine trial was put on hold in the US, Brazil and the United Kingdom but the trials have now resumed in the UK.
According to reports, the DSMB has allowed Serum Institute to restart the vaccine trials on three conditions: first, all relevant participant information must be recorded. Second, the additional safety monitory plans must be devised by SII for volunteers participating in trials and lastly the contact numbers of all participants must be recorded in case of an emergency.
About Post Author
The India Wire Team
Related
More Stories
Covishield &Covaxin prices slashed to Rs.225 from Rs.1200 and Rs.600
Vaccine makers Serum Institute of India and Bharat Biotech have reduced the price of coronavirus vaccines Covishield and Covaxin to...
23lac blessings saved 96% lung damaged mother of twin toddlers at Vadodara.
This is not just another Covid Survival story, but this is story of a movement which connected unknown people with...
Ayurveda Facts: Giloy is also known for anti ageing properties.
It’s time again to find a wave of peace in natural medicine to heal yourself. Based on many studies, Ayurveda...
Times Group Chairperson Indu Jain passed away at 84.
Times Group chairperson Indu Jain died on Thursday due to Covid-related complications, company sources said. She was 84. Hailing her...
Breaking: Dr KK Aggarwal no more; Padma Shree Awardee succumbs to COVID
After a lengthy battle with COVID-19, Dr KK Aggarwal succumbed to the virus on Monday midnight. A familiar and comforting...
Rajeev Satav passed away due to post covid complications.
Rajeev Satav began his electoral career as a block panchayat member in 2002 and went on to become both Lok...
Average Rating